Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Small Lymphocytic Lymphoma
Related studies linked through entity extraction aliases.
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Status
- RECRUITING
- Phase
- PHASE3
Study of LUCAR-20S in Patients With R/R NHL
- Status
- TERMINATED
- Phase
- PHASE1
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
- Status
- COMPLETED
- Phase
- PHASE1
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice
- Status
- UNKNOWN
- Phase
- N/A
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3